Richard Morgan, chief executive of Amphion PLC (), discusses the 'very welcome' Phase III Iclaprim news from Motif Bio.
Motif's recently revealed its lead drug, a next generation antibiotic, successfully negotiated a crucial final-stage clinical study, boosting Amphion’s shares.
Amphion owns 14.1% of Motif Bio.
Morgan says he continues to believe that Motif Bio is not fully valued compared to other comparable antibiotic companies at the same stage of development.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Amphion Innovations PLC named herein, including the promotion by the Company of Amphion Innovations PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE